Swedish Orphan Biovitrum Returns to Profit in Q3, Updates FY26 Outlook
Swedish Orphan Biovitrum said it returned to profit in the third quarter of 2026 from a year-earlier loss, helped by higher revenue, especially in Haematology. The company also updated its annual revenue outlook.